Brainsway Reports Positive Final Results of Study Using Deep TMS to Open the Blood-Brain Barrier in Patients With Brain Tumors

JERUSALEM, Feb. 21, 2012 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) is pleased to announce that it has received the final results of a clinical trial performed by Advanced Technologies Innovation Distribution SRL ("ATID") in Italy to explore the efficacy of Deep TMS in the opening of the blood-brain barrier ("BBB") in patients with brain tumors. The study was conducted in the framework of collaboration between Ben-Gurion University (Principal Investigator – Dr. Alon Friedman) and the University of Rome (Principal Investigator – Dr. Maurizio Inghilleri).